BSX - Boston Scientific Corporation
A medical device innovator specializing in minimally invasive interventions across cardiology, urology, and endoscopy.
Finlify Score
42.1 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$42.98
-0.28%
52W Range
$42.20 - $108.07
Market Cap
$70.0B
-0.3%Compared to previous day
2026 Q1 Revenue
$5.2B
-1.6%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
38 analysts in latest ratings feed
RSI
24.7
<40 oversold
2Y Range Position
1%
-60.7% from high / +1.8% from low
Beta
0.61
Relative to market benchmark
MACD
-0.75
MACD line -1.05 / signal line -0.30
Fundamental Trend
Growth 37.3Financial Health
Quality 78.5Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID42.1 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $5.2B-1.6% | $5.3B+4.4% | $5.1B+0.1% | $5.1B+8.5% |
| Gross Profit | $3.6B-1.8% | $3.7B+3.9% | $3.5B+3.5% | $3.4B+6.6% |
| Operating Income | $1.1B+33.5% | $825M-21.3% | $1.0B+28.0% | $819M-11.1% |
| Net Income | $1.3B+99.9% | $670M-11.3% | $755M-5.0% | $795M+18.3% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
Finlify's signal for BSX is AVOID, with a Finlify Score of 28.8 out of 100, which appears to be significantly influenced by very low Relative Strength and Accumulation / Volume scores, alongside a PARTIAL data quality assessment.
Technical
The asset's technical posture appears weak, indicated by a very low Relative Strength score of 2.2/100 and an Accumulation / Volume score of 19.4/100. While it has seen a recent 20-day return of 6.8%, the longer-term trend shows a 60-day return of -19.1% and the price is significantly below its 52-week high by -56.2%.
Fundamentals
Despite a relatively strong Financial Quality score of 78.5/100, the Fundamental Trend score is lower at 30.4/100. The asset trades at a P/E of 23.2x, P/B of 5.8x, and P/S of 3.4x, with a Beta of 0.6 suggesting lower volatility, based on financials up to 2026-03-31. It is noted that an EPS proxy was used, which may introduce some data quality considerations.
Macro Context
The current macro environment, characterized by a 10Y Treasury Yield of 4.7% and inflation metrics like CPI YoY at 3.7%, may present a mixed backdrop for a healthcare company like BSX. While healthcare can be defensive, higher interest rates could potentially impact future growth or financing costs.
Key Risks
- Significant technical underperformance, with a 60-day return of -19.1% and a price -56.2% from its 52-week high.
- Lower Fundamental Trend score (30.4/100) suggesting potential concerns despite higher Financial Quality.
- PARTIAL data quality and the use of an EPS proxy, which may limit the comprehensiveness of the analysis.